| Cat.No. | Name | Information |
|---|---|---|
| M6103 | Cetuximab | Cetuximab is a chimeric IgG1 monoclonal antibody to EGFR that inhibits the interaction of EGFR with its ligand. For use in cellular assays, human IgG antibody can be used as an isotype control. (For human and non-humanized mice). |
| M6102 | Pembrolizumab | Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). |
| M3849 | Aflibercept | Aflibercept is a vascular epidermal growth factor (VEGF-A and PlGF) receptor inhibitor that inhibits the growth of neovascularization. It can be used to study a variety of diseases caused by ocular neovascularization. |
| M3814 | Sarilumab | Sarilumab is a human recombinant IgG1 antibody that binds to both forms of interleukin 6 receptors (IL-6R), thus inhibiting the IL-6-mediated signaling. |
| M1629 | Ramucirumab | Ramucirumab is a direct VEGFR2 antagonist, that binds with high affinity to the extracellular domain of VEGFR2 and block the binding of natural VEGFR ligands (VEGF-A, VEGF-C and VEGF-D). |
| M1621 | Ustekinumab | Ustekinumab is a human monoclonal antibody that targets IL12 and IL23, natural proteins that regulate the immune system and immune-mediated inflammatory diseases. |
| M1618 | Vedolizumab | Vedolizumab is a humanized monoclonal antibody that specifically antagonizes Integrin (α4β7) and inhibits the binding of α4β7 to the intestinal mucosal cell adhesion molecule MADCAM-1. Vedolizumab is indicated for humanized mice. |
| M1616 | Daratumumab | Daratumumab (Daratumumab) is a first-in-class, specific anti-CD38 monoclonal antibody (IgG1). (for human or immunodeficient mice). |
| M1615 | Obinutuzumab | Obinutuzumab (GA101) is a fully humanized monoclonal antibody that binds to an epitope on CD20. |
| M1598 | Eculizumab | Eculizumab is a first-in-class recombinant humanized monoclonal antibody targeting complement protein C5. C5, which can only recognize humans, cannot bind to C5 of other species. |
| M1595 | Evolocumab | Evolocumab (AMG 145) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9). Evolocumab binds to circulating PCSK9 protein and inhibits its binding to LDLR. |
| M1545 | Infliximab | Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice. |
| M1539 | Omalizumab | Omalizumab is a recombinant DNA-derived humanized IgG1k monoclonal antibody that specifically binds to free human immunoglobulin E (IgE) and to membrane-bound form of IgE (mIgE). |
| M1527 | Ofatumumab | Ofatumumab is a humanised anti-CD20 monoclonal antibody, which appears to inhibit early-stage B lymphocyte activation. |
| M1519 | Matuzumab | Matuzumab (EMD 72000) is a humanized monoclonal antibody that binds tightly to EGFR. |
| M1512 | Nimotuzumab | Nimotuzumab (Nimotuzumab) is the first humanized monoclonal antibody targeting epidermal growth factor receptor (EGFR). Nimotuzumab has cytolytic effects on target tumors through its ability to induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement dependent cytotoxicity (CDC). Nimotuzumab failed to recognize mouse EGFR. |
| M58996 | Rolistobart | Rolistobart is a humanized immunoglobulin G4-kappa, anti-LILRB4/CD85k monoclonal antibody. |
| M58441 | Sabirnetug | Sabirnetug is a humanized IgG2κ antibody targeting the Amyloid-β A4 precursor protein. |
| M58439 | Ozekibart | Ozekibart is an anti-TNFRSF10B monoclonal antibody. |
| M58124 | Conbercept | Conbercept (KH902) is a monoclonal antibody targeting VEGFRA fused to the IGHG1 Fc fragment. Conbercept is produced by the fusion of the second C-LIKE of FLT1 and the third and fourth C-LIKE of KDR with IGHG1 Fc. |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
